AI Article Synopsis

  • * Sirolimus, a medication that inhibits the mTOR pathway, has shown promise as an effective oral treatment for various cancers and immune-related disorders.
  • * This report highlights two pediatric cases where oral sirolimus effectively treated JXG, suggesting it could provide quick disease resolution and long-term remission, prompting further research into its potential benefits for this condition.

Article Abstract

Juvenile xanthogranuloma (JXG) with extensive cutaneous or visceral organ involvement is often associated with high morbidity and treatment commonly involves surgical excision, radiotherapy, systemic steroids, or chemotherapy. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is an oral antitumor and immunosuppressive therapy used to treat various neoplastic disorders, including histiocytic disorders. We report two pediatric cases of JXG successfully treated with oral sirolimus monotherapy, and postulate that sirolimus may induce rapid disease resolution and long-term remission for patients with both skin-limited and multisystemic JXG. Our findings warrant further investigation of the relationship between the mTOR pathway and JXG.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.15579DOI Listing

Publication Analysis

Top Keywords

oral sirolimus
8
juvenile xanthogranuloma
8
report pediatric
8
pediatric cases
8
sirolimus treatment
4
treatment juvenile
4
xanthogranuloma report
4
cases juvenile
4
jxg
4
xanthogranuloma jxg
4

Similar Publications

Background: Recent studies show that hyperactivation of mTOR (mammalian target of rapamycin) signaling plays a causal role in the development of thoracic aortic aneurysm and dissection. Modulation of PP2A (protein phosphatase 2A) activity has been shown to be of significant therapeutic value. In light of the effects that PP2A can exert on the mTOR pathway, we hypothesized that PP2A activation by small-molecule activators of PP2A could mitigate AA progression in Marfan syndrome (MFS).

View Article and Find Full Text PDF

Background: Blue rubber bleb nevus syndrome (BRBNS) is a rare venous malformation disorder. Currently, there is no standard therapy for this disease. However, lauromacrogol, a sclerosant extensively utilized in the management of vascular malformations, has been applied in the treatment of BRBNS.

View Article and Find Full Text PDF

Background: Rhabdomyoma is the most common cardiac tumor in fetal life. It has frequent association with tuberous sclerosis complex and may lead to heart failure, a potentially fatal condition. The use of transplacental sirolimus, a mTOR inhibitor, has emerged as a novel treatment in symptomatic fetal rhabdomyomas, there are, though, only few cases described.

View Article and Find Full Text PDF

Regulatory role of the mTOR signaling pathway in autophagy and mesangial proliferation in IgA nephropathy.

Zhong Nan Da Xue Xue Bao Yi Xue Ban

August 2024

Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha 410011.

Objectives: IgA nephropathy (IgAN) is the most common primary glomerular disease in China, but its pathogenesis remains unclear. This study aims to explore the regulatory role of the mammalian target of rapamycin (mTOR) signaling pathway in autophagy and mesangial proliferation during renal injury in IgA.

Methods: The activity of mTOR and autophagy was evaluated in kidney samples from IgAN patients and in an IgAN mouse model induced by oral bovine serum albumin and carbon tetrachloride (CCl4) injection.

View Article and Find Full Text PDF

Arteriovenous malformations (AVMs) are rare congenital vascular malformations with associated morbidities. We describe a neonatal case of upper limb high-flow AVM presenting with upper limb soft tissue mass and postnatal high-output heart failure. Doppler study suggested high-flow AVM, and later magnetic resonance angiography of the right upper limb confirmed the diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!